Individualized antithrombotic therapy on one patient with chronic renal insufficiency

Abstract

Abstract:

AIM: To evaluate the role of clinical pharmacist in individualized antithrombotic therapy on patients with chronic renal insufficiency. METHODS: To review clinical pharmacist participating antithrombotic therapy on one patient with chronic renal insufficiency. RESULTS:Clinical pharmacist analyzed the causes of chronic renal failure and skin hematoma formation by pharmacokinetic and pharmacodynamic characteristics of aspirin and enoxaparin, participated the adjustment of antithrombotic therapy and implemented pharmaceutical care and pharmaceutical edueation for the patlents. CONCLUSION: Clinical pharmacist focuses on individualized medication of special crowd which could be the entry points for pharmaceutical care, avoid adverse reactions and ensure the reasonable, safety, effec, and economy of drug in patients.

Key words: chronic renal insufficiency, aspirin, skin hematoma, enoxaparin, clinical pharmacist, individualized medication

CLC Number:

R972

DANG Xiangji, ZHOU Lin, WANG Yixuan, ZENG Lu. Individualized antithrombotic therapy on one patient with chronic renal insufficiency[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(4): 477-480.

References

［1］Généreux P, Stone GW, Harrington RA, et al. Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX trial (Clinical trial comparing cangrelor to clopidogrel standard of care therapy in subjects who require percutaneous coronary intervention)［J］. J Am Col Cardiol, 2014, 63(7): 619-629.
［2］Rothwell PM, Price JF, Fowkes FGR, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials［J］. Lancet, 2012, 379(9826): 1602-1612.
［3］Song Y, Tang XF, Zhang JH, et al. TCT-206 effect of the α2A-adrenergic receptor genetic variants on platelet reactivity and adverse clinical events in Chinese patients with dual antiplatelet therapy after percutaneous coronary intervention［J］. J Am Col Cardiol, 2015, 66(15): B79.
［4］Amut E, Umrr Y, Jia DM, et al. Practice and experience of developing drug administration in primary hospital［J］. Chin Pharm，2015, 50(7): 650-652.
［5］Luo M, Wu B, Wu FB, et al. Impact of pharmacist-participa-ted anticoagulation service on warfarin therapy management:A systematic review［J］. Chin Pharm J, 2015, 50(61): 554-558.
［6］Lin JP. According to the norm of heparin clinical application［J］. Chin J MOD Drug Appl, 2011, 5(20): 65-66.
［7］Zhang QX, Wang YL. Kidney damage associated with low-dose of enteric-coated aspirin tablets in 16 patients［J］. ADRJ, 2004, 6(2): 82-82.
［8］Stankovic I, Vlahovic-Stipac A, Putnikovic B, et al. Concomitant administration of simvastatin and danazol associated with fatal rhabdomyolysis［J］. Clin Ther, 2010, 32(5): 909.
［9］刘艺平, 徐萍, 李焕德. 氯吡格雷的药学监护［C］. 2010 年中国药学大会暨第十届中国药师周论文集, 2010.
［10］韩雅玲, 王守力, 李毅, 等. 急性冠状动脉综合征患者冠状动脉支架术前高负荷量氯吡格雷预治疗近期疗效［J］. 中国介入心脏病学杂志, 2005, 13(1): 9-12.
［11］Mcquaid KR, Laine L. System atic review and metaanalysis of adverse even ts of lowdose asp irin and clop idogrel in random izedcon trolled trials［J］. Am J Med, 2006, 119 (8): 624-638.
［12］Seshasai SRK, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials［J］. Arch Inter Med, 2012, 172(3): 209-216.
［13］徐佑龙, 刘宗军. 不同中药在抗血小板药物抵抗患者中的研究［J］. 长春中医药大学学报, 2014, 30(1): 34-36.
［14］Fung ZH, Yu TL. Aspirin on renal damage in primary hypertension, 186 cases of clinical analysis［J］. J Huaxi Med, 1999, 14(3): 307.

[1]	ZHANG Zhaowei, LI Zuojun, HUANG Jian, LI Shuangqing, HE YiLin. Exploring the outbreak point for clinical pharmacists to provide pharmaceutical care in nephrology department [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 184-188.
[2]	YU Yahong, SONG Yu. Pharmacotherapy of patients with left ventricular assist devices [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 198-204.
[3]	XU Tao, ZHU Suyan, QIU Xiangjun, XU Ping. Population pharmacokinetics of teicoplanin in patients with renal insufficiency [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 977-983.
[4]	WU Yuanzhu, LIU Jun, YANG Kui, PENG Jing, LUAN Jiajie, WEI Jun, ZHANG Dafa, SONG Shuai, YUAN Xiaolong, WANG Zhongfang, ZHANG Nianbao, XIE Dan, JIANG Peng, FAN Jie. Distribution of CYP2C9*3 and VKORC1-1639G>A gene polymorphism in Anhui Han population and their influence on the stable dose of warfarin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 652-659.
[5]	ZENG Xiaofan, XU Yiqi, LIU Shu, WU Qian, LI Zibao, HE Junjun, JIN Yuelong, ZHAO Yongli, HE Chunling, GAO Jialin. Retrospectively analysis of the effect of low-dose aspirin on primary prevention of non-fatal myocardial infarction and cerebral infarction in patients with type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 665-671.
[6]	LU Xiya, LI Yuxing, LI Wenzhi, PENG Yuanyuan, HU Yi, WAN Li, CHEN Bilian. Analysis of prescribing of antiplatelet drug in patients with coronary heart disease in department of geriatrics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1285-1291.
[7]	LI Lihua, ZHANG Shengpeng, QIN Jiaxu, NIAN Sihui. Protective effects of the extract from Toona sinensis seeds on gastric mucosa injury in experimental mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 546-551.
[8]	XIA Chunyong, ZHANG Zuowen, HE Xiaoyan, LIU Jie, LI Xiaoya, CHANG Qiuhong, QIN Lijuan, CAO Zhenming, DING Ling. Correlation between CYP2C19 gene polymorphism and individualized medication in patients with ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 318-323.
[9]	ZHOU Haihui, ZHANG Haixia, GE Weihong. Analysis of the role of clinical pharmacist in the establishment of standardized cancer pain management ward [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1038-1042.
[10]	ZHANG Haowen, ZHU Yejin, WU Xiang, CHEN Hanyu, SONG Yulei, BIAN Yaoyao, HAO Haiping, CHEN Xiaohu. Study on high on-aspirin platelet reactivity in diabetic mice based on metabonomics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 246-256.
[11]	YANG Rui, LIU Hui, CHEN Zeheng, QI Tingting，ZHANG Zanling, QU Qiang. Clinical pharmacists use CYP2C19 genotyping test to guide individual medication therapy of Clopidogrel and to evaluate the efficacy of treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 938-943.
[12]	FANG Xi, QU Qiang, XIAO Xiangcheng. Advances in the treatment of tacrolimus in idiopathic membranous nephropathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 228-234.
[13]	YUAN Yumei, WANG Ronghua, YANG Shuixin. Pharmaceutical service in statinsinduced Rhabdomyolysis by clinical pharmacists [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 704-708.
[14]	ZHU Xuting, HANG Yongfu. Clinical pharmacists' pharmaceutical care and practice in the department of nephrology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1174-1178.
[15]	LI Nan，HUANG Haitao，YONG Xiaolan. Pharmaceutical care for a patient misdiagnosed as Staphylococcus intermedius pulmonary infection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(9): 1067-1071.